Genmab — November 2020

[Stockwatch1]

DnB: Today Genmab announced that it will not advance the
development of enapotamab vedotin (EV), citing that
the data did not meet its stringent criteria for proof-ofconcept. This confirms the company’s strategy to end
projects that are not efficacious enough and we believe
it will be likely to also scrap DR5/DR5. Genmab’s focus
is on progressing already-partnered projects. We
reiterate our HOLD but have cut our target price to
DKK2,320 (2,352).

[bibob]

Er du lige stået op Stockwatch. ;-). Se E L 08.32

[kkjoel]

Indlæg fra Macabo 09:04 ("EA kind of a weak up call - Pensionisten i dere s morgen brev fra PB") forstår jeg ikke en dyt af. Lyder som en af de der noter fundet i en gammel stok eller i en begravet metalæske, som Tintin regelmæssigt prøver på at dechiffrere Jeg efterlyser en minimal anstrengelse for at skrive noget forståeligt...

[Stockwatch1]

Bibob, jeg har haft travlt til morgen og har ikke set at det allerede er postet. Troede ikke der var andre der havde adgang til DnB

[Klarussen]

Så er jeg med på holdet igen, tankede godt op i 2185 i går og solgte lidt i dag (for tidligt) i 2210. Kunne ikke blive ved med at vente på 2150 Fantastisk firma, fantastisk fremtid, fantastisk chef og fantastisk forum Skulle den ramme 2150 tanker jeg videre op der.

[lahn1]

Blev CD47 CPI TTI-622 afskrevet som mulig combi med DAR ?

[E_L]

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Wednesday, setting a price target of $44

[Helge_LarsenPI-redaktør]

Upcoming Events : https://ir.genmab.com/events-and-presentations#content

[kkjoel]

@pens - jeg citerede blot Macabo. Du kunne jo starte med at læse det indlæg, der er henvist til!

[kkjoel]

Men Macabo tror jeg ikke kommer til at svare.. så fred med det

[E_L]

Janssen's Teclistamab Received FDA Orphan Drug Designation for Treatment of Multiple Myeloma on November 24

[Darvin]

Måske nævnt - men nyt kursmål i US: Truist Securities raises target price to $42 from $41

[E_L]

@peter12 did you listen to the whole Novartis call or only the CEO intro?

[bibob]

NICE : new option in cancerdrugs. https://www.nice.org.uk/news/article/new-option-for-people-with-difficult-to-treat-multiple-myeloma-is-recommended-for-use-in-cancer-drugs-fund-by-nice

[peter12]

@EL_ I think its still online ? But that was what he said

[Sukkeralf]

It also provided its own 2025 sales estimates for a number of key brands, including established growth drivers – Cosentyx ($5.6 billion), Entresto ($4.9 billion) and Kisqali ($1.6 billion), recent launches – Zolgensma ($2 billion), Kesimpta ($1.8 billion) and Piqray ($1.3 billion) - and the approval pending inclisiran ($1.4 billion).

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[E_L]

yes, i heard that , but i stopped after 1/2 hour, because they did not follow the presentation anymore, too long to sit through everything, i was wondering if they said more later on, on the number of subscriptions

[E_L]

in the presentation it reads : 95%+ (~6000) of MS prescribing targets reached

[E_L]

Solsen thought that means 6,000 prescriptions, I am not so sure, so hoping for clarification